Raynaud phenomenon: from GWAS to drug repurposing

Research output: Contribution to journalComment/debate


The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α 2A-adrenoceptors, and suggests opportunities for drug repurposing.

Original languageEnglish
Pages (from-to)139-140
Number of pages2
JournalNature Reviews. Rheumatology
Issue number3
Early online date16 Jan 2024
Publication statusPublished - 1 Mar 2024


  • Drug Repositioning
  • Genome-Wide Association Study
  • Humans
  • Raynaud Disease/drug therapy


Dive into the research topics of 'Raynaud phenomenon: from GWAS to drug repurposing'. Together they form a unique fingerprint.

Cite this